Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.
Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.